Key result
GLP-1 receptor agonists and SGLT2 inhibitors lead all pharmacological classes for HbA1c reduction and cardiorenal benefits.
Why the study?
Do pharmacological interventions reduce HbA1c levels in adults with diabetes?
Systematic Review
Do pharmacological interventions reduce HbA1c levels in adults with diabetes?
Answers are grounded in this paper and cite their sources.
GLP-1 receptor agonists and SGLT2 inhibitors are highly effective for HbA1c reduction and provide additional cardiovascular, renal, and weight loss benefits in adults with diabetes.
BACKGROUND: Glycated hemoglobin (HbA1c) is a widely used biomarker for monitoring long-term glycemic control in individuals with diabetes. It reflects average blood glucose levels over the past 2–3 months and is crucial for diagnosing diabetes and guiding treatment decisions. Maintaining optimal HbA1c levels is essential in preventing diabetes-related complications. OBJECTIVE: This systematic review aims to evaluate and summarize the current pharmacological interventions available for HbA1c reduction, focusing on their efficacy, safety, and clinical implications in diabetes management. METHODS: We conducted a comprehensive search of studies published between 2019 and 2024 from databases including PubMed, Scopus, and Cochrane Library. Inclusion criteria focused on randomized controlled trials and observational studies assessing pharmacological interventions for HbA1c reduction in adults with diabetes. Key outcomes included changes in HbA1c levels, adverse events, and treatment-related complications. RESULTS: The review identifies GLP-1 receptor agonists and SGLT2 inhibitors as the most effective pharmacological classes for HbA1c reduction, offering significant benefits in terms of weight loss and cardiovascular and renal outcomes. Insulin and sulfonylureas remain widely used, though their efficacy is tempered by the risk of hypoglycemia and weight gain. Newer agents, such as dual GLP-1/GIP receptor agonists, show promising results but require further long-term data. CONCLUSION: Pharmacological interventions for HbA1c reduction continue to evolve, with newer therapies providing substantial benefits beyond glycemic control. Clinicians should adopt a personalized treatment approach based on individual patient needs, including comorbidities and treatment tolerability. Future research should focus on long-term safety, combination therapies, and pharmacogenomics insights to refine treatment strategies and enhance patient outcomes.
No takes yet. Share an insight, caveat, or question.
Upadhye et al. (2025) conducted a systematic review in Diabetes. Pharmacological interventions was evaluated on Changes in HbA1c levels, adverse events, and treatment-related complications. GLP-1 receptor agonists and SGLT2 inhibitors were the most effective pharmacological classes for HbA1c reduction, offering significant weight loss and cardiorenal benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: